Business
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)
Moderate Alzheimer’s disease (AD) patients in the trial received the highest dose of troculeucel to date at 6 billion cells per treatment. After 12 months of treatment, both patients who completed 17 doses improved from moderate to mild AD within just 3 months. One patient stabilized at their improved score, while the other patient continued to show ongoing improvement. Clinical development of troculeucel is ongoing and will be evaluated for safety and efficacy in the randomized, placebo-control
About this update from Nkgen Biotech Inc.
[{"type":"image","alt":"NKGen Biotech, Inc.","displaySize":"","headline":null,"caption":"NKGen Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/6148ed3e2e28e6c539be48d0406ad510"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XRU5Bz8FlnWhn7nRqZ2pow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6148ed3e2e28e6c539be48d0406ad510","width":300,"height":88}},"lazy":false},{"type":"text","content":"Moderate Alzheimer’s disease (AD) patients in the trial received the highest dose of troculeucel to date at 6 billion cells per treatment.","length":138,"tagName":"p"},{"type":"text","content":"After 12 months of treatment, both patients who completed 17 doses improved from moderate to mild AD within just 3 months. One patient stabilized at their improved score, while the other patient continued to show ongoing improvement.","length":233,"tagName":"p"},{"type":"text","content":"Clinical development of troculeucel is ongoing and will be evaluated for safety and efficacy in the randomized, placebo-controlled Phase 2a part of the study.","length":158,"tagName":"p"},{"type":"text","content":"SANTA ANA, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics, today announced the oral presentation of updated Phase 1 clinical data from the Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate AD at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2025) in Vienna, Austria.","length":622,"tagName":"p"},{"type":"text","content":"Dr. Paul Y. Song, Chairman and Chief Executive Officer of NKGen Biotech, delivered an oral presentation to conference attendees which was focused on the six and twelve-month cognitive and biomarker results from the Phase 1 cohort of the Phase 1/2a clinical trial for troculeucel NK cell therapy in moderate Alzheimer’s disease (NCT06189963).","length":341,"tagName":"p"},{"type":"text","content":"Highlights from the presentation:","length":33,"tagName":"p"},{"type":...